Bendamustine is effective in T-Cell prolymphocytic leukaemia-Reference-Cited by-同舟云学术

Bendamustine is effective in T-Cell prolymphocytic leukaemia

Published:2014-10-15 Issue:6 Volume:168 Page:916-919
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Herbaux Charles¹,Genet Philippe²,Bouabdallah Krimo³,Pignon Jean-Michel⁴,Debarri Houria¹,Guidez Stéphanie¹,Betrian Sarah⁵,Leleu Xavier¹,Facon Thierry¹,Morschhauser Franck¹,Damaj Gandhi⁶,Cazin Bruno¹,Ysebaert Loïc⁵

Affiliation:

1. Service des Maladies du Sang; Centre Hospitalier Régional et Universitaire de Lille; Lille France

2. Service d'Hématologie; Centre Hospitalier d'Argenteuil; Argenteuil France

3. Service d'Hématologie; Centre Hospitalier Universitaire de Bordeaux; Bordeaux France

4. Service d'Hématologie; Centre Hospitalier de Dunkerque; Dunkerque France

5. Service d'Hématologie; Institut Universitaire du Cancer de Toulouse; Toulouse France

6. Service d'Hématologie clinique et Thérapie cellulaire; Oncopôle CHU d'Amiens; Amiens France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13175/fullpdf

Reference10 articles.

1. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial;Damaj;Journal of Clinical Oncology,2013

2. How I treat prolymphocytic leukemia;Dearden;Blood,2012

3. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H;Dearden;Blood,2001

4. Phase I trial of nelarabine in indolent leukemias;Gandhi;Journal of Clinical Oncology,2008

5. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories;Herling;Blood,2004

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolymphocytic Leukaemia: an Update on Biology and Treatment;Current Oncology Reports;2024-01-02

2. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment;International Journal of Molecular Sciences;2023-07-28

3. Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline;British Journal of Haematology;2021-11-22

4. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia;Blood;2021-06-24

5. Papuloerythroderma heralding recurrence of an aggressive T-cell Leukemia;Current Problems in Cancer: Case Reports;2021-03